Twenty-eight renowned researchers, including Josep M. Canals and Unai Perpiñá from the Production and Validation Centre of Advanced Therapies (Creatio) at the University of Barcelona, have created the Stem Cells for Huntington's Disease (SC4HD) consortium to promote advanced therapy medicinal products (ATMP) for Huntington’s Disease.
The main goals of SC4HD are to work together with the Huntington’s Disease community, develop criteria and guidance and address the main challenges to quickly and safely bring potentially beneficial stem cell-based therapies to patients.
The researchers are based in ten different countries.
SC4HD was officially announced in a recent issue of the Journal of Huntington’s Disease.
Comments